UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 21, 2017
Immunomedics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 000-12104 | 61-1009366 | ||
(State
or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS
Employer Identification No.) |
300 The American Road, Morris Plains, New Jersey | 07950 | |
(Address of principal executive offices) | (Zip Code) |
(973)
605-8200
(Registrant’s telephone
number,
including area code
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure.
On February 21, 2017, Immunomedics, Inc. issued a press release titled “Immunomedics Files Federal Lawsuit against venBio for Continuing Material Violations of the Federal Securities Laws.” The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description of Exhibit | |
99.1 | Press Release of Immunomedics, Inc., dated February 21, 2017, titled “Immunomedics Files Federal Lawsuit against venBio for Continuing Material Violations of the Federal Securities Laws.” |
2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNOMEDICS, INC. | ||
By: | /s/ Michael R. Garone | |
Name: | Michael R. Garone | |
Title: | Vice
President, Finance and Chief Financial Officer | |
Date: February 21, 2017 |
3 |
Exhibit Index
Exhibit Number |
Description | |
99.1 | Press Release of Immunomedics, Inc., dated February 21, 2017, titled “Immunomedics Files Federal Lawsuit against venBio for Continuing Material Violations of the Federal Securities Laws.” |
4